An Alzheimer’s drug could prevent dementia symptoms before they become obvious, with research suggesting it could clear toxic brain plaques in just three months.
Trontinemab, a medicine given as a monthly infusion, will be offered to about 1600 people across the world who do not yet have memory problems but indicate a high risk of the disease - to see whether it can stave off symptoms.
Scientists said the landmark trial could be “a gamechanger”, raising the prospect of “statins for the brain” being routinely offered to people in mid-life.
The phase III trial – the final pre-approval testing stage for a new treatment – will use blood tests to identify those most likely to benefit from taking part.
People aged 55 and over who are “cognitively unimpaired” but have biomarkers linked to the development of Alzheimer’s will be invited to take part.
Trontinemab, manufactured by the Swiss pharmaceutical firm Roche, works by removing sticky amyloid plaques that aggregate in the brain and cause the degenerative disease.
It is a next-generation version of lecanemab and donanemab, the first Alzheimer’s drugs to slow the disease’s progression.
Trontinemab has been designed to reach the brain more efficiently than its predecessors and appears to have fewer side effects, so could require less monitoring, bringing down costs.
The new research suggests trontinemab can remove amyloid plaques much quicker than existing treatments.
Hilary Evans-Newton, the chief executive of Alzheimer’s Research UK, said: “The science is advancing rapidly, and every new discovery brings us closer to a future where diseases can be identified and treated much earlier.
“Over the next five to 10 years, we will see a transformation in what’s possible, including the prospect of treatments that help protect brain health before symptoms progress – the concept of a ‘statin for the brain’.”
Trontinemab is administered through a drip in a hospital and analysis suggests brains of patients receiving the highest dose would be free of dementia-causing amyloid after three infusions.
Top-up doses every three months are enough to keep plaque levels low for 18 months, data show.
It has yet to be seen whether the drug’s ability to remove plaque also prevents cognitive decline in the way shown with the previous Alzheimer’s drugs.
Lecanemab and donanemab were found to slow cognitive decline in symptomatic patients by 27% and 35% respectively.
The prevention study for trontinemab, known as PrevenTRON, will recruit cognitively healthy volunteers in countries across the world, aged between 55 and 80.
Volunteers will have tested positive for elevated levels of the biomarker p-tau217, which is found in the blood and linked to Alzheimer’s disease.
Younger participants will need additional genetic or family risk factors to be considered.
Dr Rachel Buckley, associate professor of neurology at Harvard Medical School, said the new generation of treatments being trialled was “wonderful”, adding that she hoped to see success in cognitively unimpaired individuals in the coming 12 to 24 months.
She said: “If these trials are positive, the game changes.”
Dr Jacqui Hanley, head of research funding at Alzheimer’s Research UK, said the latest findings were encouraging, and she called for larger trials to show whether the drugs made a “meaningful impact” to people’s lives.
She said: “PrevenTRON is part of an important shift in research, from focusing on people who already have symptoms towards finding those most at risk and seeing whether treatment can delay, or perhaps one day prevent symptoms developing. It raises the exciting possibility that Alzheimer’s could eventually be treated preventively, in a similar way to using medicines to reduce the risk of heart attacks and strokes.”
Sign up to Herald Premium Editor’s Picks, delivered straight to your inbox every Friday. Editor-in-Chief Murray Kirkness picks the week’s best features, interviews and investigations. Sign up for Herald Premium here.